Project neuroARTEMIS

Plain-language summary

This study looks at the ARTEMIS intervention together with a contingency-management approach to support antiretroviral therapy adherence in people living with HIV who use stimulants. It enrolls people aged 18-59 with confirmed HIV who take daily oral antiretroviral therapy and report recent stimulant use. It is a non-phase study and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Recruiting

Sponsor

Wake Forest University Health Sciences

Intervention

ARTEMIS, Contingency management for Antiretroviral (ARV) adherence

Start date

4/29/2025

Estimated completion

12/31/2028

Countries

United States

Related genes

Locations

• Winston-Salem, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* 18-59 years old
* Weekly use of stimulants reported in the past month or a score of 4 or more on the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)
* Confirmed HIV diagnosis
* Current receipt of daily oral antiretroviral therapy (ART) medication
* English fluency/literacy

Exclusion Criteria:

* Acute brain infection (e.g., neurosyphilis, toxoplasmosis)
* Acutely symptomatic bipolar I or psychotic disorder
* Prescription for immunomodulatory medications or other immunotherapy
* Any MRI contraindications
* If applicable, on antidepressant medication regimen for at least 2 months